Comparing the current results to its competitors, Abcellera Biologics Inc reported Revenue increase in the 1 quarter 2026 by 96.34 % year on year. The sales growth was above Abcellera Biologics Inc 's competitors' average revenue growth of 22.57 %, achieved in the same quarter.
Abcellera Biologics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 34.77 %
Abcellera Biologics Inc 's Comment on Competition and Industry Peers
The company utilizes proprietary expertise, specialized multidisciplinary teams, and integrated physical infrastructure to develop medicines. Its strategy is indication-agnostic, focusing on programs with strong scientific foundations, significant commercial potential, differentiation opportunities, and clear development pathways. The company has established a pipeline in endocrinology, women’s health, immunology, autoimmunity, and oncology. Its platform combines data collection and computational tools to enhance productivity and decision-making. The company prioritizes internal programs that leverage its technological advantages and assesses each program individually for clinical development feasibility.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
Sources:
Abcellera Biologics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Abcellera Biologics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
